CNSP CNS Pharmaceuticals, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1729427 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-22.3%
TTM EPS YoY-102.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-124.8%
ROA-106.8%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets13.1%
Debt / equity0.00x
Current ratio7.65x
Interest coverage-1,031.22x
Cash quality & payout
Operating cash flow / net income0.88x
Accruals ratio-13.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $890,000 | $1.20M | $3.54M | $3.17M | $2.20M | $1.17M | $3.24M | $1.50M |
| SG&A expense | $1.77M | $1.50M | $1.43M | $2.82M | $1.06M | $1.24M | $1.09M | $1.70M |
| Operating income | -$2.67M | -$2.70M | -$4.98M | -$5.99M | -$3.25M | -$2.41M | -$4.34M | -$3.20M |
| Interest expense | $3,000 | $4,000 | $6,111 | $2,721 | $2,000 | $4,000 | $6,208 | $2,774 |
| Net income | -$2.50M | -$2.59M | -$4.94M | -$5.96M | -$3.22M | -$2.38M | -$4.30M | -$3.18M |
| EBITDA | -$2.67M | -$2.69M | -$4.97M | -$5.99M | -$3.25M | -$2.41M | -$4.34M | -$3.20M |
| EPS (basic) | -0.24 | -0.38 | -7.30 | — | -5.76 | -6.42 | -18.93 | — |
| EPS (diluted) | -0.24 | -0.38 | -7.30 | — | -5.76 | -6.42 | -18.93 | — |
| Weighted avg. shares (diluted) | 10.61M | 6.84M | 676,172 | — | 558,868 | 370,127 | 227,220 | — |
| Balance sheet | ||||||||
| Cash & equivalents | $17.21M | $19.98M | $2.95M | $7.20M | $9.86M | $12.13M | $13.05M | $6.46M |
| Current assets | $18.05M | $21.92M | $4.08M | $8.10M | $11.39M | $14.14M | $13.72M | $8.66M |
| PP&E, net | $14,000 | $15,000 | $22,014 | $18,000 | $3,107 | $3,804 | $4,905 | $6,005 |
| Total assets | $18.06M | $21.94M | $4.65M | $8.62M | $11.87M | $14.51M | $13.75M | $8.70M |
| Current liabilities | $2.36M | $3.74M | $4.58M | $4.10M | $1.96M | $1.38M | $2.78M | $2.52M |
| Total liabilities | $2.36M | $3.74M | $4.58M | $4.10M | $1.96M | $1.38M | $2.78M | $2.52M |
| Shareholders' equity | $15.71M | $18.20M | $71,000 | $4.52M | $9.91M | $13.12M | $10.97M | $6.18M |
| Shares outstanding | 1.48M | 1.46M | 811,449 | 632,516 | 574,580 | 504,413 | 2.94M | 117,796 |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.77M | -$3.54M | -$4.65M | -$3.05M | -$2.17M | -$5.34M | -$3.24M | -$5.47M |
| Capital expenditure | $0 | $3,821 | $6,179 | $18,175 | $0 | $0 | $0 | $4,188 |
| Free cash flow | -$2.77M | -$3.54M | -$4.65M | -$3.07M | -$2.17M | -$5.34M | -$3.24M | -$5.48M |
| Investing cash flow | $0 | -$3,821 | -$6,179 | -$18,175 | $0 | $0 | $0 | -$4,188 |
| Financing cash flow | $0 | $20.58M | $404,660 | $406,872 | -$92,000 | $4.43M | $9.83M | $4.96M |
| Depreciation & amortization | $0 | $11,132 | $1,868 | $1,020 | $1,000 | $1,101 | $1,100 | $985 |
| Stock-based compensation | $25,000 | $2,000 | $2,555 | $85,068 | $19,000 | $22,000 | $62,367 | $129,900 |
Free plan shows the latest 8 periods; Pro shows all 35 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.